STOCK TITAN

Zymeworks Inc. (ZYME) EVP Mark discloses stock and RSU holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Zymeworks Inc. executive Hollywood Mark, EVP & Chief Operating Officer, filed an initial ownership report showing his equity stake in the company as of January 9, 2026. He directly owns 121,367 shares of common stock. In addition, he holds several stock options to buy common shares, including 80,000 options at $15.23 expiring in 2029 and other grants through 2035 at exercise prices ranging from $7 to $35.20. Mark also holds restricted stock units, with 20,000 RSUs from a January 2024 grant and 53,000 RSUs from a January 2025 grant, each RSU representing the right to receive one share of common stock upon vesting.

Positive

  • None.

Negative

  • None.
Insider Hollywood Mark
Role EVP & Chief Operating Officer
Type Security Shares Price Value
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Restricted Stock Unit -- -- --
holding Restricted Stock Unit -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 80,000 shares (Direct); Restricted Stock Unit — 20,000 shares (Direct); Common Stock — 121,367 shares (Direct)
Footnotes (1)
  1. Stock option granted March 27, 2019. Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Stock option granted March 10, 2020. Stock option granted March 10, 2021. Stock option granted March 10, 2022. Stock option granted January 5, 2023. Stock option granted January 5, 2024. Stock option granted January 10, 2025. 60,000 restricted stock units ("RSUs") granted January 5, 2024; vest in three equal annual installments beginning January 5, 2025. As of January 9, 2026, 20,000 RSUs remain outstanding. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. 53,000 restricted stock units ("RSUs") granted January 10, 2025; vest in three equal annual installments beginning January 10, 2026. As of January 9, 2026, 53,000 RSUs remain outstanding.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Hollywood Mark

(Last) (First) (Middle)
C/O ZYMEWORKS INC.
108 PATRIOT DRIVE, SUITE A

(Street)
MIDDLETOWN DE 19709

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/09/2026
3. Issuer Name and Ticker or Trading Symbol
Zymeworks Inc. [ ZYME ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & Chief Operating Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 121,367 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (1)(2) 03/26/2029 Common Stock 80,000 $15.23 D
Stock Option (Right to Buy) (2)(3) 03/09/2030 Common Stock 24,375 $35.2 D
Stock Option (Right to Buy) (2)(4) 03/09/2031 Common Stock 30,000 $34.82 D
Stock Option (Right to Buy) (2)(5) 03/09/2032 Common Stock 90,000 $7 D
Stock Option (Right to Buy) (2)(6) 01/04/2033 Common Stock 61,000 $8 D
Stock Option (Right to Buy) (2)(7) 01/04/2034 Common Stock 90,000 $10.56 D
Stock Option (Right to Buy) (2)(8) 01/09/2035 Common Stock 79,000 $13.22 D
Restricted Stock Unit (9) (9) Common Stock 20,000 (10) D
Restricted Stock Unit (11) (11) Common Stock 53,000 (10) D
Explanation of Responses:
1. Stock option granted March 27, 2019.
2. Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
3. Stock option granted March 10, 2020.
4. Stock option granted March 10, 2021.
5. Stock option granted March 10, 2022.
6. Stock option granted January 5, 2023.
7. Stock option granted January 5, 2024.
8. Stock option granted January 10, 2025.
9. 60,000 restricted stock units ("RSUs") granted January 5, 2024; vest in three equal annual installments beginning January 5, 2025. As of January 9, 2026, 20,000 RSUs remain outstanding.
10. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
11. 53,000 restricted stock units ("RSUs") granted January 10, 2025; vest in three equal annual installments beginning January 10, 2026. As of January 9, 2026, 53,000 RSUs remain outstanding.
Remarks:
Exhibit List - Exhibit 24 - Power of Attorney
/s/ Daniel Dex, Attorney-in-Fact 01/13/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider reporting holdings in Zymeworks Inc. (ZYME)?

The insider is Hollywood Mark, who serves as EVP & Chief Operating Officer of Zymeworks Inc..

How many Zymeworks Inc. common shares does Hollywood Mark own?

Hollywood Mark directly owns 121,367 shares of common stock of Zymeworks Inc.

What stock options does Hollywood Mark hold in Zymeworks Inc.?

He holds multiple stock options (Right to Buy), including 80,000 options at $15.23 expiring on March 26, 2029, plus additional option grants through March 9, 2032, January 4, 2033, January 4, 2034, and January 9, 2035 at exercise prices from $7 to $35.20.

What restricted stock units (RSUs) are reported by Hollywood Mark for Zymeworks Inc.?

He reports 20,000 RSUs remaining from a 60,000 RSU grant on January 5, 2024, and 53,000 RSUs from a grant on January 10, 2025. As of January 9, 2026, all 53,000 RSUs from the 2025 grant remain outstanding.

How do Hollywood Mark’s RSUs in Zymeworks Inc. vest?

The 60,000 RSUs granted on January 5, 2024 vest in three equal annual installments beginning January 5, 2025. The 53,000 RSUs granted on January 10, 2025 vest in three equal annual installments beginning January 10, 2026.

What does each Zymeworks Inc. RSU reported by Hollywood Mark represent?

Each restricted stock unit (RSU) represents the contingent right to receive, upon vesting, one share of Zymeworks Inc. common stock.